Eleven IPOs raised a combined $3.8 billion in January, the busiest month for both $100+ million and $1+ billion IPOs since late 2021. Six offerings raised $100 million or more, led by two billion-dollar deals: sports gear maker Amer Sports (AS)...read more
Seven IPOs priced this past week, led by three that raised $100+ million. After upwardly revising the terms earlier in the week, CG Oncology (CGON) further upsized the offering and priced above the range to raise $380 million at a $1.3...read more
ArriVent Biopharma, a Phase 3 biotech developing a novel kinase inhibitor for EGFR-mutated lung cancer, raised $175 million by offering 9.7 million shares at $18, within the range of $17 to $19. The company offered 1.4 million more shares than anticipated. ...read more
ArriVent Biopharma, a Phase 3 biotech developing a novel kinase inhibitor for cancer, announced terms for its IPO on Monday. The Newtown Square, PA-based company plans to raise $150 million by offering 8.3 million shares at a price range of $17 to $19. At the...read more
Renaissance Capital's January IPO Market Update
Eleven IPOs raised a combined $3.8 billion in January, the busiest month for both $100+ million and $1+ billion IPOs since late 2021. Six offerings raised $100 million or more, led by two billion-dollar deals: sports gear maker Amer Sports (AS)...read more
US IPO Weekly Recap: Biotech CG Oncology pops 96% in a 7 IPO week
Seven IPOs priced this past week, led by three that raised $100+ million. After upwardly revising the terms earlier in the week, CG Oncology (CGON) further upsized the offering and priced above the range to raise $380 million at a $1.3...read more
Cancer biotech ArriVent BioPharma prices upsized IPO at $18 midpoint
ArriVent Biopharma, a Phase 3 biotech developing a novel kinase inhibitor for EGFR-mutated lung cancer, raised $175 million by offering 9.7 million shares at $18, within the range of $17 to $19. The company offered 1.4 million more shares than anticipated. ...read more
Cancer biotech ArriVent BioPharma sets terms for $150 million IPO
ArriVent Biopharma, a Phase 3 biotech developing a novel kinase inhibitor for cancer, announced terms for its IPO on Monday. The Newtown Square, PA-based company plans to raise $150 million by offering 8.3 million shares at a price range of $17 to $19. At the...read more